# US 2025/0145729 A1 · Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145729 A1
- Document ID: US20250145729A1
- Status: Published application
- Kind: A1
- Application number: 18/716,489
- Filed: 2022-12-16
- Published: 2025-05-08
- Earliest claimed: 2021-12-17
- Assignees: Denali Therapeutics Inc.
- Applicants: Denali Therapeutics Inc.
- Inventors: Padma Akkapeddi; Gerald Maxwell Cherf; Kylie S. Chew; Mark S. Dennis; Zhenyu Gu; Mihalis S. Kariolis; Hai L. Tran; Robert C. Wells; Joy Yu Zuchero
- Web page: https://patentgrep.com/patent/US20250145729A1

## CPC

- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/005: {constructed by phage libraries}
- C07K 16/2881: {against CD71}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- A61K 2039/505: {comprising antibodies}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure includes engineering methods and polypeptide libraries that are useful for introducing non-native binding sites into polypeptides. Also provided herein are polypeptides that bind to a CD98hc or transferrin receptor (TfR) protein, methods of generating such polypeptides, and methods of using the polypeptides to target a composition across the blood-brain barrier or to a CD98hc-expressing or TfR-expressing cell.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A polypeptide comprising a modified CH3 domain that specifically binds to a CD98hc protein, wherein the modified CH3 domain comprises a sequence having at least 95% sequence identity to amino acids 111-217 of the sequence of any one of SEQ ID NOS:28-43, wherein the modified CH3 domain comprises at least eleven, twelve, thirteen, fourteen, or fifteen substitutions in a set of amino acid positions consisting of a L at position 380, a N or S at position 382, a R, H, or Q at position 384, a F or Y at position 385, a V, L, I, F, Y, or E at position 386, a L at position 387, a E, Q, or A at position 421, a I, T, or P at position 422, an A at position 424, a N at position 426, a Y or W at position 428, a R or W at position 436, a F or W at position 438, a N at position 440, and an A, Q, K, R, H, or M at position 442, according to EU numbering.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The polypeptide of claim 9, wherein:
(a) the modified CH3 domain comprises a L at position 380, a N at position 382, a H at position 384, a Y at position 385, a E at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(b) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an E at position 421, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(c) the modified CH3 domain comprises a L at position 380, a N at position 382, a H at position 384, a Y at position 385, a E at position 386, a L at position 387, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(d) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442;
(e) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and a R at position 442; or
(f) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and a H at position 442; or
(g) the modified CH3 domain comprises a L at position 380, a N at position 382, a H at position 384, a Y at position 385, a E at position 386, a L at position 387, an E at position 421, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(h) the modified CH3 domain comprises a L at position 380, a N at position 382, a Q at position 384, a Y at position 385, a E at position 386, a L at position 387, an E at position 421, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(i) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(i) the modified CH3 domain comprises a L at position 380, a N at position 382, a Q at position 384, a Y at position 385, a E at position 386, a L at position 387, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(k) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a R at position 436, a F at position 438, a N at position 440, and a R at position 442; or
(1) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and a K at position 442; or
(m) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a W at position 436, a F at position 438, a N at position 440, and a R at position 442; or
(n) the modified CH3 domain comprises a L at position 380, a N at position 382, a Q at position 384, a Y at position 385, a L at position 386, a L at position 387, an E at position 421, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(o) the modified CH3 domain comprises a L at position 380, a S at position 382, a R at position 384, a Y at position 385, a V at position 386, a L at position 387, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(p) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an E at position 421, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442; or
(q) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an E at position 421, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, and a N at position 440; or
(r) the modified CH3 domain comprises a L at position 380, a N at position 382, a Q at position 384, a F at position 385, a H at position 386, a L at position 387, an I at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and a L at position 442; or
(s) the modified CH3 domain comprises a L at position 380, a N at position 382, a R at position 384, a F at position 385, a V at position 386, a L at position 387, an T at position 422, an A at position 424, a N at position 426, a Y at position 428, a F at position 438, a N at position 440, and an A at position 442.

### Claim 12 (depends on 11)

The polypeptide of claim 11, wherein the modified CH3 domain comprises a sequence selected from any one of SEQ ID NOS:38, 29, 31, 32, 35, 36, 28, 30, 37, 41, 42, 43, 33, 34, 39, and 40.

### Claim at position 6

13-43. (canceled)

### Claim 44 (depends on 9)

The polypeptide of claim 9, wherein the polypeptide:
(a) binds human CD98hc with an affinity of 15 nM to 5 μM; and/or
(b) has cyno cross-reactivity; and/or
(c) binds to cyno CD98hc with an affinity of 80 nM to 5 μM.

### Claim at position 8

45-50. (canceled)

### Claim 51

A polypeptide comprising a modified CH3 domain that specifically binds to a CD98hc protein, wherein the modified CH3 domain comprises a sequence having at least 95% sequence identity to amino acids 111-217 of the sequence of any one of SEQ ID NOS:44-45, wherein the modified CH3 domain comprises at least eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen substitutions in a set of amino acid positions consisting of a R at position 382, a T at position 383, a Y at position 384, a K at position 385, a P at position 386, a Y at position 387, a T at position 389, a D at position 421, an I at position 422, a V at position 424, a D at position 426, a L at position 428, a F at position 436, a I at position 438, and a K at position 440, according to EU numbering.

### Claim 52

(canceled)

### Claim 53 (depends on 51)

The polypeptide of claim 51, wherein:
(a) the modified CH3 domain comprises a R at position 382, a T at position 383, a Y at position 384, a K at position 385, a P at position 386, a Y at position 387, a T at position 389, a D at position 421, an I at position 422, a V at position 424, a D at position 426, a F at position 436, a I at position 438, and a K at position 440; or
(b) wherein the modified CH3 domain comprises a R at position 382, a T at position 383, a Y at position 384, a K at position 385, a P at position 386, a Y at position 387, a T at position 389, a D at position 421, an I at position 422, a V at position 424, a D at position 426, a L at position 428, a F at position 436, a I at position 438, and a K at position 440.

### Claim 54 (depends on 53)

The polypeptide of claim 53, wherein the modified CH3 domain comprises SEQ ID NO:44 or SEQ ID NO:45.

### Claim at position 13

55-140. (canceled)

### Claim 141 (depends on 9)

The polypeptide of claim 9, wherein the modified CH3 domain further comprises at least one modification that promotes heterodimerization; and/or wherein the polypeptide further comprises L at position 428 and S at position 434.

### Claim 142 (depends on 141)

The polypeptide of claim 141, wherein the at least one modification that promotes heterodimerization comprises a T366W substitution, according to EU numbering; or
wherein the at least one modification that promotes heterodimerization comprises T366S, L368A, and Y407V substitutions, according to EU numbering.

### Claim 143

(canceled)

### Claim 144

(canceled)

### Claim 145 (depends on 9)

The polypeptide of claim 9, wherein the polypeptide further comprises a modified CH2 domain comprising modifications that reduce effector function, wherein the modifications that reduce effector function comprise A1a at position 234 and A1a at position 235 and/or Gly or Ser at position 329, according to EU numbering.

### Claim at position 19

146-151. (canceled)

### Claim 152 (depends on 9)

The polypeptide of claim 9, wherein:
(a) the polypeptide is part of a dimer; and/or
(b) the polypeptide is further joined to a Fab; and/or
(c) the C-terminal lysine of the polypeptide is absent.

### Claim 153

(canceled)

### Claim 154

(canceled)

### Claim 155 (depends on 152)

The polypeptide of claim 152, wherein the polypeptide is a first polypeptide of a dimer such that the dimer is monovalent for CD98hc binding; or wherein the polypeptide is a first polypeptide of a dimer such that the dimer is bivalent for CD98hc binding.

### Claim at position 24

156-159. (canceled)

### Claim 160 (depends on 9)

A polynucleotide comprising a nucleic acid sequence encoding the polypeptide of claim 9.

### Claim 161 (depends on 160)

A vector or host cell comprising the polynucleotide of claim 160.

### Claim 162

(canceled)

### Claim 163 (depends on 160)

A method for producing a polypeptide comprising a modified constant domain or modified CH3 domain, comprising culturing a host cell under conditions in which the polypeptide encoded by the polynucleotide of claim 160 is expressed.

### Claim 164 (depends on 9)

A pharmaceutical composition comprising the polypeptide of claim 9 and a pharmaceutically acceptable carrier.

### Claim 165 (depends on 9)

A method of transcytosis across an endothelium, comprising contacting the endothelium with a composition comprising the polypeptide of claim 9 fused to a therapeutic agent.

### Claim 166

(canceled)

### Claim 167

(canceled)

### Claim 168 (depends on 165)

The method of claim 165, wherein the endothelium is the BBB.

### Claim at position 34

169-178. (canceled)

### Claim 179 (depends on 165)

The method of claim 165, further comprising delivering the therapeutic agent to a biological target in the brain.

### Claim at position 36

180-203. (canceled)

### Claim 204

A method of increasing brain exposure to a therapeutic agent in a subject relative to a reference molecule, the method comprising administering to the subject a monovalent molecule that binds to CD98hc with a binding affinity from about 20 nM to about 550 nM or a bivalent molecule that binds to CD98hc with a binding affinity from about 275 nM to about 2100 nM, wherein the molecule is linked to the therapeutic agent, and wherein the reference molecule comprises the therapeutic agent but not a CD98hc binding moiety.

### Claim at position 38

205-287. (canceled)
